FR2871379B1 - Utilisation de derives polysaccharidiques hautement sulfates et de faible masse molaire pour moduler l'angiogenese - Google Patents

Utilisation de derives polysaccharidiques hautement sulfates et de faible masse molaire pour moduler l'angiogenese

Info

Publication number
FR2871379B1
FR2871379B1 FR0406405A FR0406405A FR2871379B1 FR 2871379 B1 FR2871379 B1 FR 2871379B1 FR 0406405 A FR0406405 A FR 0406405A FR 0406405 A FR0406405 A FR 0406405A FR 2871379 B1 FR2871379 B1 FR 2871379B1
Authority
FR
France
Prior art keywords
derivatives
polysaccharide derivatives
low molecule
molecular weight
sulfated polysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0406405A
Other languages
English (en)
French (fr)
Other versions
FR2871379A1 (fr
Inventor
Sabine Matou
Jouault Sylvia Colliec
Dominique Helley
Jacqueline Ratiskol
Corinne Sinquin
Claire Boisset
Jean Guezennec
Anne Marie Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Francais de Recherche pour lExploitation de la Mer (IFREMER)
Original Assignee
Institut Francais de Recherche pour lExploitation de la Mer (IFREMER)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0406405A priority Critical patent/FR2871379B1/fr
Application filed by Institut Francais de Recherche pour lExploitation de la Mer (IFREMER) filed Critical Institut Francais de Recherche pour lExploitation de la Mer (IFREMER)
Priority to JP2007515983A priority patent/JP5148272B2/ja
Priority to AT05775263T priority patent/ATE540685T1/de
Priority to US11/629,544 priority patent/US7833990B2/en
Priority to PCT/FR2005/001378 priority patent/WO2006003289A2/fr
Priority to AU2005259078A priority patent/AU2005259078B2/en
Priority to EP20050775288 priority patent/EP1755620B1/de
Priority to CA2570224A priority patent/CA2570224C/fr
Priority to US11/629,579 priority patent/US20080131472A1/en
Priority to CA 2570199 priority patent/CA2570199C/fr
Priority to AU2005259077A priority patent/AU2005259077B2/en
Priority to AT05775288T priority patent/ATE510546T1/de
Priority to FR0505740A priority patent/FR2871476B1/fr
Priority to PCT/FR2005/001379 priority patent/WO2006003290A2/fr
Priority to EP05775263A priority patent/EP1765366B1/de
Priority to ES05775263T priority patent/ES2385088T3/es
Priority to JP2007515984A priority patent/JP5154221B2/ja
Priority to ES05775288T priority patent/ES2367121T3/es
Publication of FR2871379A1 publication Critical patent/FR2871379A1/fr
Application granted granted Critical
Publication of FR2871379B1 publication Critical patent/FR2871379B1/fr
Priority to US12/986,820 priority patent/US8598142B2/en
Priority to US14/052,133 priority patent/US9125883B2/en
Priority to US14/822,477 priority patent/US10105393B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0666—Mesenchymal stem cells from hair follicles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
FR0406405A 2004-06-14 2004-06-14 Utilisation de derives polysaccharidiques hautement sulfates et de faible masse molaire pour moduler l'angiogenese Expired - Fee Related FR2871379B1 (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
FR0406405A FR2871379B1 (fr) 2004-06-14 2004-06-14 Utilisation de derives polysaccharidiques hautement sulfates et de faible masse molaire pour moduler l'angiogenese
EP05775263A EP1765366B1 (de) 2004-06-14 2005-06-06 Wundheilende verwendung von sulfatierten depolymerisierten exopolysaccharidderivate
PCT/FR2005/001379 WO2006003290A2 (fr) 2004-06-14 2005-06-06 Derives depolymerises sulfates d'exopolysaccharides (eps) preparation et utilisations
PCT/FR2005/001378 WO2006003289A2 (fr) 2004-06-14 2005-06-06 Derives de polysaccharide sulfates pour moduler l’angiogenese
AT05775263T ATE540685T1 (de) 2004-06-14 2005-06-06 Wundheilende verwendung von sulfatierten depolymerisierten exopolysaccharidderivate
EP20050775288 EP1755620B1 (de) 2004-06-14 2005-06-06 Sulfierte depolymerisierte exopolysaccharidderivate, ihre herstellung und verwendungen
CA2570224A CA2570224C (fr) 2004-06-14 2005-06-06 Derives depolymerises sulfates d'exopolysaccharides (eps) provenant de bacteries marines mesophiles, leur procede de preparation et leurs utilisations en regeneration tissulaire
ES05775263T ES2385088T3 (es) 2004-06-14 2005-06-06 Uso de derivados de exopolisacáridos (EPS) despolimerizados sulfatados, como cicatrizantes
CA 2570199 CA2570199C (fr) 2004-06-14 2005-06-06 Utilisation de derives de polysaccharide hautement sulfates et de faible masse molaire pour moduler l'angiogenese
AU2005259077A AU2005259077B2 (en) 2004-06-14 2005-06-06 Use of low-molecular-weight highly sulfated polysaccharide derivatives for modulating angiogenesis
JP2007515983A JP5148272B2 (ja) 2004-06-14 2005-06-06 血管新生を調節するための低分子量の高度に硫酸化された多糖誘導体の使用
FR0505740A FR2871476B1 (fr) 2004-06-14 2005-06-06 Derives depolymerises sulfates d'exopolysaccharides (eps) provenant de bacteries marines mesophiles, leur procede de preparation et leurs utilisations en regeneration tissulaire
US11/629,544 US7833990B2 (en) 2004-06-14 2005-06-06 Use of low-molecular-weight highly sulfated polysaccharide derivatives for modulating angiogenesis
AU2005259078A AU2005259078B2 (en) 2004-06-14 2005-06-06 Sulfated depolymerized derivatives of exopolysaccharides (EPS) from mesophilic marine bacteria, method for preparing same, and uses thereof in tissue regeneration
US11/629,579 US20080131472A1 (en) 2004-06-14 2005-06-06 Sulfated Depolymerized Derivatives of Exopolysaccharides (Eps) from Mesophilic Marine Bacteria, Method for Preparing Same, and Uses Thereof in Tissue Regeneration
JP2007515984A JP5154221B2 (ja) 2004-06-14 2005-06-06 中温性海洋細菌由来のエクソポリサッカリド（ｅｐｓ）の硫酸化脱重合誘導体、その調製方法、及び組織再生におけるその使用
ES05775288T ES2367121T3 (es) 2004-06-14 2005-06-06 Derivados de exopolisacaridos (eps) despolimerizados sulfatados, su preparación y sus usos.
AT05775288T ATE510546T1 (de) 2004-06-14 2005-06-06 Sulfierte depolymerisierte exopolysaccharidderivate, ihre herstellung und verwendungen
US12/986,820 US8598142B2 (en) 2004-06-14 2011-01-07 Sulfated depolymerized derivatives of expolysaccharides (EPS) from mesophilic marine bacteria, method for preparing the same, and uses thereof in tissue regeneration
US14/052,133 US9125883B2 (en) 2004-06-14 2013-10-11 Sulfated depolymerized derivatives of exopolysaccharides (EPS) from mesophilic marine bacteria, method for preparing same, and uses thereof in tissue regeneration
US14/822,477 US10105393B2 (en) 2004-06-14 2015-08-10 Sulfated depolymerized derivatives of exopolysaccharides (EPS) from mesophilic marine bacteria, method for preparing same, and uses thereof in tissue regeneration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0406405A FR2871379B1 (fr) 2004-06-14 2004-06-14 Utilisation de derives polysaccharidiques hautement sulfates et de faible masse molaire pour moduler l'angiogenese

Publications (2)

Publication Number Publication Date
FR2871379A1 FR2871379A1 (fr) 2005-12-16
FR2871379B1 true FR2871379B1 (fr) 2006-09-29

Family

ID=34946349

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0406405A Expired - Fee Related FR2871379B1 (fr) 2004-06-14 2004-06-14 Utilisation de derives polysaccharidiques hautement sulfates et de faible masse molaire pour moduler l'angiogenese

Country Status (9)

Country Link
US (5) US7833990B2 (de)
EP (2) EP1755620B1 (de)
JP (2) JP5148272B2 (de)
AT (2) ATE510546T1 (de)
AU (2) AU2005259078B2 (de)
CA (2) CA2570199C (de)
ES (2) ES2367121T3 (de)
FR (1) FR2871379B1 (de)
WO (2) WO2006003290A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2894147B1 (fr) * 2005-12-07 2008-02-15 Ifremer Utilisation d'un polysaccharide excrete par l'espece vibrio diabolicus a des fins de regeneration et de protection du parodonte
JP2007204396A (ja) * 2006-01-31 2007-08-16 Pias Arise Kk マトリックスメタロプロテアーゼ−９及びエンドセリン−１の産生抑制剤、並びにその産生抑制剤を配合した炎症後色素沈着の予防・改善剤、化粧料
KR101537834B1 (ko) * 2008-04-15 2015-07-20 루카스 마이어 코스메틱스 캐나다 인크. 미생물 매트로부터 유래된 엑소폴리사카라이드를 포함하는 화장료 조성물
WO2010086696A1 (en) * 2009-01-28 2010-08-05 Therapol Low-molecular-weight sulphated polysaccharides as candidates for anti-angiogenic therapy
FR2953217B1 (fr) 2009-11-27 2012-10-05 Ifremer Procede de depolymerisation de polysaccharides par broyage mecanique
CN101856658B (zh) * 2010-06-01 2011-09-07 云南大红山管道有限公司 一种长距离铁精矿管道软堵塞的疏通方法
FR2964014B1 (fr) * 2010-08-31 2013-04-05 Ifremer Nucleus enrobe d'un revetement filmogene aux proprietes antibacteriennes et cicatrisantes et procede d'obtention.
ES2390033B1 (es) 2010-11-30 2013-10-31 Lipotec S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas.
JP6100451B2 (ja) * 2011-01-18 2017-03-22 ヒノキ新薬株式会社 皮膚外用剤
WO2012126824A1 (en) 2011-03-18 2012-09-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Chondrogenic differentiation media and methods for inducing chondrogenic differentiation of cells
ES2424294B1 (es) * 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP3146971A1 (de) * 2015-09-28 2017-03-29 Institut Francais de Recherche pour l'Exploitation de la Mer (IFREMER) Antimetastatisches derivat aus marinen bakteriellen exopolysacchariden und verwendungen davon
WO2017118979A1 (en) * 2016-01-07 2017-07-13 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Compositions and methods for generating immunotolerant responses
JP2019530663A (ja) 2016-09-01 2019-10-24 インスティトゥート デ ビオロジア モレクラル エ セルラル−イーベーエミセーＩｎｓｔｉｔｕｔｏ Ｄｅ Ｂｉｏｌｏｇｉａ Ｍｏｌｅｃｕｌａｒ Ｅ Ｃｅｌｕｌａｒ − Ｉｂｍｃ シアノバクテリア細胞外ポリマー、組成物およびそれらの使用
AU2021301259A1 (en) * 2020-07-02 2023-02-02 Fondation Sanfilippo Suisse Marine bacterial exopolysaccharide derivatives and uses thereof in the treatment of mucopolysaccharidoses
EP4112060A1 (de) 2021-07-01 2023-01-04 Institut Francais de Recherche pour l'Exploitation de la Mer (IFREMER) Niedermolekulare he800-exopolysaccharidderivate mit antikrebs-eigenschaften und ihre verwendungen
CN116731221B (zh) * 2023-06-26 2024-03-12 益得来(深圳)健康科技有限公司 一种多糖衍生物及其在制药中的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4102566A (en) * 1977-05-02 1978-07-25 Foster Grant Corporation Rimless spectacle
JPS58121799A (ja) * 1982-01-14 1983-07-20 Microbial Chem Res Found 多糖類ｍｐ−８６物質およびその製造法
IT1214609B (it) 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
FR2701488B1 (fr) * 1993-02-15 1995-05-05 Ifremer Bactéries du type Alteromonas, polysaccharides produits par ces bactéries, ose contenu dans ces polysaccharides et applications.
US6255296B1 (en) * 1994-01-11 2001-07-03 Endomatrix, Inc. Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease
JP2986376B2 (ja) * 1995-06-16 1999-12-06 株式会社ホリカワ リムレス眼鏡におけるブリッジ及びリムレス眼鏡
US5985330A (en) * 1996-08-05 1999-11-16 Coastside Bio Resources Inhibition of angiogenesis by sea cucumber fractions
US5828307A (en) * 1996-09-23 1998-10-27 Phillips Petroleum Company Hydrocarbon gas monitor desk
FR2755142B1 (fr) * 1996-10-30 1999-01-15 Ifremer Souche bacterienne marine du genre alteromonas, exopolysaccharides hydrosolubles produits par cette souche, et leurs utilisations
US5847800A (en) * 1996-12-13 1998-12-08 Tachibana; Hideaki Lens holding mechanism of spectacles
JP4051099B2 (ja) 1997-01-31 2008-02-20 生化学工業株式会社 低分子化ヘパリン、その製造法及び医薬組成物
FR2760022B1 (fr) 1997-02-25 1999-04-30 Ifremer Souche bacterienne marine du genre vibrio, polysaccharides hydrosolubles produits par cette souche, et leurs utilisations
FR2780063B1 (fr) * 1998-06-22 2001-07-13 Ifremer Polysaccharide purifie d'alteromonas macleodii et ses utilisations
US6024445A (en) * 1998-11-04 2000-02-15 Microvision Optical, Inc. Single point attachment of bridge and temples to eyeglass lenses
IT1302534B1 (it) * 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
FR2797768B1 (fr) * 1999-09-01 2003-06-13 Ifremer Utilisation d'un polysaccharide sulfate de bas poids moleculaire pour l'obtention d'un medicament actif contre la thrombose vasculaire
FR2811229B1 (fr) * 2000-07-04 2003-08-01 Ifremer Utilisation d'un polysaccharide excrete par l'espece vibrio diabolicus en cicatrisation osseuse
MXPA04012714A (es) * 2002-06-18 2005-08-15 Glycores 2000 Srl Derivados epimerizados del polisacarido k5 con un grado muy alto de sulfatacion.
US7736636B2 (en) * 2003-02-12 2010-06-15 Shaker Mousa Method for treating occlusive vascular diseases & wound healing

Also Published As

Publication number Publication date
ES2385088T3 (es) 2012-07-18
US7833990B2 (en) 2010-11-16
WO2006003289A3 (fr) 2006-05-04
EP1755620B1 (de) 2011-05-25
US20140037597A1 (en) 2014-02-06
CA2570224A1 (fr) 2006-01-12
US20070259833A1 (en) 2007-11-08
US20150344848A1 (en) 2015-12-03
EP1765366B1 (de) 2012-01-11
EP1755620A2 (de) 2007-02-28
FR2871379A1 (fr) 2005-12-16
US8598142B2 (en) 2013-12-03
ATE540685T1 (de) 2012-01-15
ES2367121T3 (es) 2011-10-28
WO2006003290A2 (fr) 2006-01-12
EP1765366A2 (de) 2007-03-28
WO2006003289A2 (fr) 2006-01-12
JP5148272B2 (ja) 2013-02-20
AU2005259078B2 (en) 2011-03-31
CA2570199A1 (fr) 2006-01-12
JP5154221B2 (ja) 2013-02-27
US10105393B2 (en) 2018-10-23
AU2005259078A1 (en) 2006-01-12
WO2006003290A3 (fr) 2006-05-04
AU2005259077B2 (en) 2011-01-20
AU2005259077A1 (en) 2006-01-12
US9125883B2 (en) 2015-09-08
CA2570224C (fr) 2015-08-04
ATE510546T1 (de) 2011-06-15
JP2008502762A (ja) 2008-01-31
CA2570199C (fr) 2013-08-06
AU2005259078A2 (en) 2006-01-12
US20080131472A1 (en) 2008-06-05
JP2008502763A (ja) 2008-01-31
US20110245199A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
ATE510546T1 (de) Sulfierte depolymerisierte exopolysaccharidderivate, ihre herstellung und verwendungen
Kim et al. Injectable hyaluronic acid–tyramine hydrogels for the treatment of rheumatoid arthritis
Dahiya et al. Hyaluronic acid: a boon in periodontal therapy
Kogan et al. Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications
Hintze et al. Chemical modification of hyaluronan and their biomedical applications
Bansal et al. Hyaluronic acid: a promising mediator for periodontal regeneration
Maccari et al. Isolation and structural characterization of chondroitin sulfate from bony fishes
Kuo Practical aspects of hyaluronan based medical products
ES2632947T3 (es) Gel de ácido hialurónico para inyección intradérmica
Volpi et al. Role, metabolism, chemical modifications and applications of hyaluronan
Weindl et al. Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects
ES2539152T3 (es) Aislamiento e identificación de glucosaminoglucanos
ES2214628T3 (es) Compuestos farmaceuticos que comprenden una mezcla de acido hialuronico autorreticulado y acido hialuronico no reticulado y su utilizacion para el tratamiento de artropatias.
ES2670932T3 (es) Nuevo biomaterial a partir de la gelatina de Wharton del cordón umbilical humano
CA2598331C (en) Amide derivatives of hyaluronic acid in osteoarthrosis
DE60042325D1 (de) Iniezierbare hyaluronat-sulphatierte polysaccharid konjugate
CN101686936A (zh) 天然多糖凝胶剂在制备用于治疗关节退行性变的可注射制剂中的应用
CN105979968A (zh) 具有持久性的透明质酸凝胶组合物
EA200802307A1 (ru) Бинарные смеси гиалуроновой кислоты и их терапевтическое применение
WO2009150651A4 (en) Injectable hydrogel forming chitosan mixtures
Zhao et al. Preparation of heparan sulfate-like polysaccharide and application in stem cell chondrogenic differentiation
RU2012134096A (ru) Гидрогель, содержащий микросферы
Farias et al. A novel antinociceptive sulphated polysaccharide of the brown marine alga Spatoglossum schroederi
WO2012177257A1 (en) Adhesive cell tissue gels
CN107530371B (zh) 硫酸乙酰肝素的pdgf-b/pdgf-bb结合变体

Legal Events

Date Code Title Description
AU Other action affecting the ownership or exploitation of an industrial property right
TQ Partial transmission of property
ST Notification of lapse

Effective date: 20150227